Jeffrey Connaire, MD
Nephrology · Minneapolis, MNNPI 1710931449
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,425 of the $10,842 with a category attached, or 68.5%. 5 manufacturers reported payments, led by GSK at 46.8% of the total. Reporting peaked in 2020 at $4,725 and has fallen 99.7% since, to $16 in 2024. Among nephrology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $401.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- Travere Therapeutics, Inc.$5K
- Bayer$1K
- Vertex$42
- Aurinia Pharma U.S., Inc.$16
Across 81 payments — averaging $7776.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$270K
- Astrazeneca UK Limited$137K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$123K
- CSL Behring$40K
- GSK$31K
- Gilead$13K
- plus $16K from 4 others
What the payments were for
- Consulting fees$7,42568%
- Travel & lodging$2,44823%
- Food & beverage$9699%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $5,077 |
| Travere Therapeutics, Inc. | 10 | $4,518 |
| Bayer | 11 | $1,190 |
| Vertex | 1 | $42 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
How this compares
$10,842 in reported general payments places this provider in the 90th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 16 | $237 |
| Losartan Potassium | 17 | $218 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $137 |
| Chlorthalidone | 15 | $133 |
| Lisinopril | 32 | $128 |
| Amlodipine Besylate | 11 | $123 |
| Potassium Chloride | 13 | $54 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Minneapolis
- Kirsten JohansenMinneapolis$101K
- Jeffrey KohenMinneapolis$56K
- James WetmoreMinneapolis$48K
- Robert FoleyMinneapolis$12K
- Patrick NachmanMinneapolis$7K
- Charles SmithMinneapolis$4K
- Mirna BoumitriMinneapolis$3K
- Jiwan ThapaMinneapolis$3K
- Suzanne SwanMinneapolis$2K
- Arda AkolukMinneapolis$777
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.